
Previously, dupilumab (Dupixent) received orphan drug designation for bullous pemphigoid.

Previously, dupilumab (Dupixent) received orphan drug designation for bullous pemphigoid.

The vaccine is the first virus-like particle single-dose vaccine for chikungunya for patients 12 years and older.

Denosumab-dssb is approved as a 60 mg pre-filled syringe as a biosimilar for Prolia and 120 mg vial as a biosimilar for Xgeva.

The combination includes 2 previously approved vaccines to target the 5 major serogroups of Neisseria meningitidis.

Currently, blood-thinning medications are only prescribed to patients who have already had a heart attack or stroke, as the drugs can cause serious bleeding.

The drug is the first rapid-acting insulin biosimilar product approved for use by the FDA, marking a significant milestone in diabetes treatment.

Identifying women who are at risk for postpartum depression sooner can lead to quicker and possibly preventative treatment.

Investigators note there were no safety signals related to the vaccine candidate, and participants who developed E. coli disease received treatment and care.

A dose response is observed with the highest dose of the drug and mitigating withdrawal symptoms for patients with cannabis use disorder.

For weight loss and antihypertensive effects on systolic and diastolic blood pressure, semaglutide also had increased effects.

The tablet formation of risdiplam (Evrysdi) demonstrates bioequivalence to the oral formulation of the drug.

The designation is based on the AMULET phase 2 trial, which was the first-in-human study of the drug.

Data has shown the investigational cell therapy is well-tolerated in patients and showed preliminary impacts on cognition.

Recently, there has been concern around glucagon-like peptide-1 receptor agonists and increase the risk of thyroid cancer, with liraglutide having a black box warning label for the disease.

Social media can help close the gap on health care information access, but pharmacists still play a large role in diabetes management, especially in therapeutics.

Poor cardiometabolic health is associated with cognitive impairment in later life, but there is no clear association between cardiometabolic trajectories and early markers.

Expert highlights the benefits of using apomorphine infusion to provide more consistent medication levels and reduce the unpredictable fluctuations.

Data from a previous phase 1b trial show improvements in the Eczema Area and Severity Index (EASI)-75 compared with the placebo at 12 weeks.

Patients who achieved clinical remission at 1 year in VIVID-1 maintain clinical remission at 92.9% at 2 years with the Crohn Disease Activity Index.

The survey results show 1 in 4 Americans ranked health care access and affordability as their highest public health priority for government officials to address.

With the acceptance of the new drug application and granting priority review, the target action date is August 12, 2025.

App notifications can be effected by various notification focuses, software updates, or connecting hardware, such as car audio or wireless earphones.

The prevalence of high blood pressure is highest in Mississippi at 40.2% compared with the lowest in Colorado at 24.6%.

ADI-001 is an investigation allogeneic gamma delta chimeric antigen receptor T cell therapy that targets CD20 for the treatment of a variety of autoimmune diseases.

Primary hyperoxaluria type 1 (PH1) is a rare genetic condition that affects the kidney, bladder, or urinary tract, and indicates high levels of oxalates in the urine.

Investigators also find that the proportion of patients that were admitted to the intensive care unit after hospital admission was much higher for Black rural patients.

The therapy is now the first and only FDA-approved treatment that maintains vision with fewer treatments compared to standard-of-care injections.

Sodium-glucose cotransporter 2 inhibitors are more cardioprotective in older adults and glucagon-like peptide-1 receptor agonists for younger patients.

The drug will be made available in the second quarter of 2025.

Approximately 29% of patients were also more likely to refill their medication, leading investigators to consider an association between medication adherence.